nav-left cat-right
cat-right

Screening Europe, February 17-18 2015 Berlin, Germ...

Screening Europe is back! After a break of four years during which we covered screening topics within the European LabAutomation event, SELECTBIO is delighted to re-introduce this popular conference. Hot topics to be covered include 3D cell based screening methods, the use of model organisms, and novel approaches for data analysis. Focus will also be given to the evolving use of phenotypic screening. Attending this event will...

New screening strategy introduced to develop possi...

Scientists have developed a new drug-discovery strategy, which will help them in rapidly selecting chemical compounds that will have a desired effect on cells. Researchers from the Scripps Research Institute (TSRI) has also tried to highlight how these compounds will work. Scientists have identified a compound that shows promise for treating obesity-linked diabetes by using the innovative technique, and were able to identify...

Two-Layer Screen Locates Both Drugs and Targets

Scripps researchers are exploring a new screening method that combines a phenotype-based screen for compounds with a desired cellular effect, and a target-based screen to determine which molecular pathways are being affected. Rather than a purely phenotypic model, which often reveals promising drugs but does not reveal why they work, or a purely target-based model, which may exclude effective compounds because they do not hit...

Online resources supporting drug discovery

Abstract Online resources enabling and supporting drug discovery have blossomed during the past ten years. However, drug hunters commonly find themselves overwhelmed by the proliferation of these computer-based resources. Ten years ago, we, the authors of this review, felt that a comprehensive list of in silico resources relating to drug discovery was needed. Especially because the internet provides a wealth of inspiring...

AstraZeneca to partner with Evotec in kidney disea...

HAMBURG, Germany—Evotec AG and AstraZeneca have signed an agreement to take joint action to combat kidney diseases. Initial focus of the alliance will be exploring compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease. Under the terms of this license and collaboration agreement, AstraZeneca will receive access to a selected series of molecules...

Evotec Becomes First European CRO to Offer Agilent...

Evotec is adding Agilent Technologies’ RapidFire mass spectrometry analysis capabilities to its high-throughput screening facilities in Hamburg. RapidFire is an in-line solid-phase extraction technology. It enables ultrafast, direct analysis of native compounds for a variety of biochemical assays including routine ADME and lead discovery applications across a range of therapeutic areas. Evotec reports that it is...
Page 1 of 1712345...10...Last »